NAT10 has been demonstrated as a valuable prognostic indicator and an emerging therapeutic candidate in CRC.[26, 27] Targeting NAT10 has enhanced cancer immunotherapy efficacy by mediating macrophage reprogramming.[28] Therefore, developing nanomaterials targeting NAT10 in macrophages offers a novel treatment approach for CRC patients. This evidence concerns the gene NAT10 and colorectal carcinoma.